● Dr. Lindsay Rosenwald co-founded New York-based biotechnology investment company Opus Point Partners after a distinguished career as a practicing Philadelphia physician and as one of the first-ever Wall Street physician-analysts in the pharmaceutical sector.● He had previously established or financially developed companies that include Keryx Biopharmaceuticals, Inc., Cypress Bioscience, Inc., and Cougar Biotechnology, Inc.● Cougar made headlines in 2009 when Johnson & Johnson paid nearly $1 billion to acquire it while its innovative prostate cancer treatment drug Zytiga was still undergoing the phase II clinical trials designed to test its efficacy.
● Opus Point Partners works to create investment opportunities through hedge funds that concentrate on the development of emerging medications, as well as the health care field in general.● A joint venture that draws on the extensive medical and business experience of its founders, Opus Point Partners strategizes the most effective means of providing diversified, liquid investment vehicles that can provide a high rate of return to clients.● On its website, the company offers up-to-date reports on the biotechnology investment industry, including information on clinical trials and regulatory actions that may affect investors.
● Dr. Lindsay Rosenwald has additionally given back to his community through the establishment of the Rosenwald Foundation, which has made millions of dollars in charitable contributions. [Sources: http://opuspointpartners.com/about_us_more.php? id_content=2&id=1 ]